Co-Authors
This is a "connection" page, showing publications co-authored by Rita Nanda and Dezheng Huo.
Connection Strength
2.443
-
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer. Res Sq. 2024 Feb 01.
Score: 0.246
-
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemed J E Health. 2024 Mar; 30(3):651-663.
Score: 0.239
-
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort. Res Sq. 2023 Aug 10.
Score: 0.238
-
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. NPJ Breast Cancer. 2023 May 06; 9(1):33.
Score: 0.234
-
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
Score: 0.233
-
The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer. Res Sq. 2023 Mar 16.
Score: 0.232
-
Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer. Integr Cancer Ther. 2023 Jan-Dec; 22:15347354231185122.
Score: 0.228
-
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb; 185(3):841-849.
Score: 0.196
-
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
Score: 0.090
-
Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008 Dec 15; 14(24):7988-99.
Score: 0.086
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
Score: 0.061
-
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
Score: 0.059
-
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. NPJ Breast Cancer. 2023 Apr 14; 9(1):25.
Score: 0.058
-
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
Score: 0.058
-
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
Score: 0.058
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.052
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.047
-
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
Score: 0.027